These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28804127)

  • 1. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
    Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
    Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
    Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.
    He L; Tang J; Andersson EI; Timonen S; Koschmieder S; Wennerberg K; Mustjoki S; Aittokallio T
    Cancer Res; 2018 May; 78(9):2407-2418. PubMed ID: 29483097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
    Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
    Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
    Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
    Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
    Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
    Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
    Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances and Perspectives in the Treatment of T-PLL.
    Braun T; von Jan J; Wahnschaffe L; Herling M
    Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
    Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
    [No Abstract]   [Full Text] [Related]  

  • 13. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
    Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel JAK2 Fusion in T-Cell Prolymphocytic Leukemia.
    Eren OC; Stuver R; Zhou T; Zaidinski M; Moskowitz AJ; Horwitz SM; Ewalt MD; Zhang Y; Lim MS
    Genes Chromosomes Cancer; 2024 Jun; 63(6):e23252. PubMed ID: 39133763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
    Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
    Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review].
    Lai MF; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1977-1981. PubMed ID: 34893145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
    Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
    Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
    Toutah K; Nawar N; Timonen S; Sorger H; Raouf YS; Bukhari S; von Jan J; Ianevski A; Gawel JM; Olaoye OO; Geletu M; Abdeldayem A; Israelian J; Radu TB; Sedighi A; Bhatti MN; Hassan MM; Manaswiyoungkul P; Shouksmith AE; Neubauer HA; de Araujo ED; Aittokallio T; Krämer OH; Moriggl R; Mustjoki S; Herling M; Gunning PT
    J Med Chem; 2021 Jun; 64(12):8486-8509. PubMed ID: 34101461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.